Early diagnosis and institution of appropriate management for the metabolic consequences associated with psychotropic drug use in young people, such as weight gain and insulin resistance, will increase if monitoring is incorporated into routine health care; in fact, this is important before and during treatment, especially in the presence of pre-existing conditions of vulnerability, such as, in the case of our study, a certain glucose profile in the presence of a diagnosis of depression treated with sertraline. The gene discussed is INS; the disease is depressive symptom measurement.